Current Diabetes Reports最新文献_第3页

A Review of the Fear of Hypoglycemia Literature in Children and Adolescents with Type 1 Diabetes and their Caregivers. 儿童和青少年1型糖尿病患者及其照护者对低血糖的恐惧文献综述

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-03-23 DOI: 10.1007/s11892-026-01620-x

Kimberly A Driscoll, Paige J Trojanowski, Emily R Shaffer, Hannah Manis, Alicia Pardon, Cheyenne M Reynolds, Sara E Wetter-Wren, Holly K O'Donnell, Susana R Patton

引用次数: 0

Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes. 2型糖尿病患者代谢功能障碍相关脂肪变性肝病的药物治疗

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-03-14 DOI: 10.1007/s11892-026-01621-w

Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos

{"title":"Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.","authors":"Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos","doi":"10.1007/s11892-026-01621-w","DOIUrl":"10.1007/s11892-026-01621-w","url":null,"abstract":"PURPOSE OF REVIEW: Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent among individuals with type 2 diabetes (T2D). This review summarizes current evidence on the pharmacologic treatment of MASLD, with emphasis on agents currently approved for the management of T2D. RECENT FINDINGS: Among glucose-lowering therapies, GLP-1 RAs, dual GIP/GLP-1 RAs, pioglitazone, and SGLT2 inhibitors demonstrate meaningful benefits in steatohepatitis. Semaglutide provides the most robust evidence for fibrosis benefit, while data suggest potential antifibrotic effects of tirzepatide and dapagliflozin. Resmetirom and semaglutide are the only agents specifically approved for MASLD. An expanding pipeline of dual glucagon/GLP-1 and triple GIP/GLP-1/glucagon agonists such as retatrutide has shown marked reductions in liver fat and signals of MASH benefit. Additional therapies, including pan-PPAR agonists, and FGF21 analogues are advancing through phase 3 development. The therapeutic landscape is rapidly evolving toward integrated metabolic, hepatic, and cardiovascular risk reduction in T2D and MASLD. ","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12989002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD. 胰高血糖素样肽-1和双重肠促胰岛素激动剂治疗伴有外周动脉疾病的2型糖尿病：血管、心血管、代谢和死亡率结局的系统回顾和荟萃分析：肠促胰岛素治疗T2DM和PAD

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-03-10 DOI: 10.1007/s11892-026-01619-4

Larissa Araújo de Lucena, Deivyd V S Cavalcante, Marcela V Montenegro, Larissa C Hespanhol, William S de Oliveira, Juliana Q Muniz, Sruti Prathivadhi-Bhayankaram, Edgardo Kaplinsky, Alejandro Barbagelata, Juliana Giorgi

{"title":"Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD.","authors":"Larissa Araújo de Lucena, Deivyd V S Cavalcante, Marcela V Montenegro, Larissa C Hespanhol, William S de Oliveira, Juliana Q Muniz, Sruti Prathivadhi-Bhayankaram, Edgardo Kaplinsky, Alejandro Barbagelata, Juliana Giorgi","doi":"10.1007/s11892-026-01619-4","DOIUrl":"10.1007/s11892-026-01619-4","url":null,"abstract":"PURPOSE OF REVIEW: Peripheral artery disease (PAD) is a serious complication in type 2 diabetes, increasing vascular morbidity and mortality. While glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists show cardiovascular benefits in diabetes, their effects on PAD-related outcomes are unclear. This meta-analysis assessed the impact of these therapies on vascular outcomes in type 2 diabetes with PAD. RECENT FINDINGS: A systematic review and meta-analysis were conducted per PRISMA guidelines (PROSPERO CRD420251083622). PubMed, Embase, and Cochrane Central were searched. A random-effects model pooled data. Primary outcomes were major adverse limb events, peripheral revascularization, and amputation. Secondary outcomes included major adverse cardiovascular events (MACE), all-cause mortality, myocardial infarction, stroke, HbA1c, and weight changes. Six studies (four RCTs, two propensity score-matched cohorts) with 25,866 patients were included. Incretin-based therapies significantly reduced all-cause mortality (RR 0.52 [0.28–0.95], p = 0.032) and HbA1c (MD − 0.73% [–1.32 to − 0.15], p = 0.013) compared to placebo or standard care. No significant differences were found for major adverse limb events, revascularization, amputation, MACE, myocardial infarction, or stroke. Heterogeneity and low evidence certainty were noted. ","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ecological Momentary Assessment of Person-Reported Outcomes in Diabetes: Unlocking Insights with Continuous Glucose Monitoring and the Potential for Precision Medicine. 糖尿病患者报告结果的生态瞬时评估：通过持续血糖监测和精准医学潜力解锁见解。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-03-10 DOI: 10.1007/s11892-026-01618-5

Dominic Ehrmann, Norbert Hermanns, Andreas Schmitt, Laura Y Klinker, Bernhard Kulzer

{"title":"Ecological Momentary Assessment of Person-Reported Outcomes in Diabetes: Unlocking Insights with Continuous Glucose Monitoring and the Potential for Precision Medicine.","authors":"Dominic Ehrmann, Norbert Hermanns, Andreas Schmitt, Laura Y Klinker, Bernhard Kulzer","doi":"10.1007/s11892-026-01618-5","DOIUrl":"10.1007/s11892-026-01618-5","url":null,"abstract":"PURPOSE OF REVIEW: Diabetes self-management is accompanied by time-varying emotional and motivational challenges that impact mental health. These day-to-day fluctuations can be assessed via ecological momentary assessment (EMA), that allows the repeated sampling of psychosocial variables in everyday life. The benefits of EMA over questionnaires mirror the benefits of continuous glucose monitoring (CGM) over HbA1c. We describe the insights generated by combining EMA and CGM and highlight its potential. RECENT FINDINGS: Research shows that glucose levels can influence subsequent mood, stress, cognitive functioning, and symptom reporting, with nocturnal hypoglycemia and overnight glucose being particularly relevant. Studies demonstrated the importance of differentiating between subjective person-interpreted and objectively sensor-assessed glucose levels. N-of-1 analyses revealed relevant intraindividual differences in the association between glycemic and psychosocial parameters. Combining EMA and CGM can enhance our understanding of the dynamic relationship between glycemic and psychosocial variables, supporting precision medicine approaches for mental health in diabetes. ","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12975859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147431390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of GERD with Sleeve Gastrectomy: An Unintended Consequence. 胃反流与袖式胃切除术的关联：一个意想不到的后果。

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-01-29 DOI: 10.1007/s11892-025-01617-y

Jonanne Talebloo, Kishore M Gadde, Ravinder K Mittal, Ninh T Nguyen

{"title":"Association of GERD with Sleeve Gastrectomy: An Unintended Consequence.","authors":"Jonanne Talebloo, Kishore M Gadde, Ravinder K Mittal, Ninh T Nguyen","doi":"10.1007/s11892-025-01617-y","DOIUrl":"10.1007/s11892-025-01617-y","url":null,"abstract":"PURPOSE OF REVIEW: Bariatric surgery is a highly effective treatment for obesity that yields durable weight loss with significant improvement or resolution of T2D and other weight-related chronic cardiometabolic diseases. While the advantages of laparoscopic sleeve gastrectomy (LSG), the most performed bariatric surgery procedure, include procedural simplicity, short operating time, lower complication rate, durable weight loss, and significant improvement including remission of type 2 diabetes, a major drawback is gastroesophageal reflux disease (GERD). The purpose of this review is to summarize the prevalence of and predictors of GERD after LSG, physiological mechanisms that explain the risk, and novel surgical management and strategy. RECENT FINDINGS: Studies note high rates of de novo GERD and worsening of pre-existing GERD following LSG; however, estimates vary due to inconsistent definitions and length of follow-ups across the cohorts. Physiological studies demonstrate that LSG increases intragastric pressure and esophageal acid exposure in conjunction with specific anatomic alterations, which together can explain the rise in reflux seen postoperatively. Preoperative reflux, including undiagnosed preoperative GERD, is the strongest predictor of postoperative GERD. For patients with persistent GERD symptoms, conversion to gastric bypass is a common treatment, and experimental work suggests that adaptations of principles from fundoplication to sleeve anatomy can offer a pathway to minimize LSG-induced reflux. Future studies should be aimed at determining which elements of the antireflux barrier that must be preserved or reconstructed to reduce reflux after LSG. Additionally, there is a need to fully understand how the mechanics of fundoplication can be adapted and applied to sleeve anatomy to create a reliable antireflux barrier. ","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":"3"},"PeriodicalIF":7.2,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12852246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights and Advances in Physical Activity Research on Youth with Type 1 Diabetes. 青少年1型糖尿病患者体育活动研究的见解与进展

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-01-21 DOI: 10.1007/s11892-025-01614-1

Peter M Fantozzi, Susana R Patton, Christopher C Cushing

{"title":"Insights and Advances in Physical Activity Research on Youth with Type 1 Diabetes.","authors":"Peter M Fantozzi, Susana R Patton, Christopher C Cushing","doi":"10.1007/s11892-025-01614-1","DOIUrl":"10.1007/s11892-025-01614-1","url":null,"abstract":"Purpose of review: Most youth with type 1 diabetes (T1D) do not meet the guidelines for physical activity engagement, thereby diminishing potential benefits to physical and mental health. This review synthesizes the recent literature on physical activity among youth with T1D and offers recommendations for future research.Recent findings: Studies highlight challenges related to the use of inconsistent measurement tools, which prevent definitive conclusions about the mechanistic factors underlying low physical activity in youth. There has been limited research examining young children and youth newly diagnosed with T1D. Additionally, most interventions to promote physical activity in youth with T1D have involved structured and supervised exercise sessions, leaving a gap in knowledge regarding the potential impact of unstructured and unsupervised exercise interventions. To address these gaps, rigorous studies employing validated measures of physical activity in youth are needed. Interventions should incorporate developmentally appropriate behavioral science theories and emerging technologies in their design. Additional priorities include integrating diabetes technologies into clinical care, more real-world data to improve the accuracy of machine learning models for predicting dysglycemia, and advancing personalized mHealth interventions to promote physical activity in youth. While physical activity is an important area of pediatric diabetes research, gaps remain in our knowledge and intervention development. Physical activity consultations should be a part of routine diabetes care for youth. Research can inform these consultations by providing strategies to promote physical activity uptake and maintenance and by exploring ways to leverage new technologies to help youth with T1D exercise safely.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":"2"},"PeriodicalIF":7.2,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13264809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes. SGLT-2抑制剂和GLP-1受体激动剂联合治疗2型糖尿病

IF 7.2 2区医学

Current Diabetes Reports Pub Date : 2026-01-13 DOI: 10.1007/s11892-025-01616-z

Aris Liakos, Thomas Karagiannis, Ioannis Avgerinos, Eleni Bekiari

{"title":"SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes.","authors":"Aris Liakos, Thomas Karagiannis, Ioannis Avgerinos, Eleni Bekiari","doi":"10.1007/s11892-025-01616-z","DOIUrl":"10.1007/s11892-025-01616-z","url":null,"abstract":"Purpose of review: The pharmacologic management of type 2 diabetes prioritises sodium-glucose cotransporter 2 (SGLT-2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists for their demonstrated cardiovascular benefits in individuals with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors, chronic kidney disease, and heart failure. However, while current guidelines recommend these drug classes alone, combination therapy is not explicitly advocated. Herein we summarise the rationale and available evidence in support for combination therapy.Recent findings: Evidence suggests that combining SGLT-2 inhibitors and GLP-1 receptor agonists improves metabolic outcomes, including HbA1c, body weight, and blood pressure. More importantly, combination therapy can offer potential advantages for addressing residual cardiovascular risk, particularly in high-risk populations. Data from cardiovascular outcomes trials and real-world studies demonstrate consistent benefits of combination therapy across diverse subpopulations, including those with established atherosclerotic cardiovascular disease or chronic kidney disease. However, robust evidence remains limited for individuals at low cardiovascular risk, where therapy should primarily focus on metabolic goals. Of note, combination therapy faces significant barriers, including safety concerns in older or frail individuals, underutilisation in disadvantaged populations, while economic challenges may further hinder the accessibility of these therapies. Upfront combination therapy with both SGLT-2 inhibitors and GLP-1 receptor agonists could further reduce cardiovascular risk in people with type 2 diabetes, although it is crucial to pare down cost and disparities to access to maximise widespread benefits at population level.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"26 1","pages":"1"},"PeriodicalIF":7.2,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation Components of Diabetes Prevention Programs after Gestational Diabetes Mellitus: A Scoping Review. 妊娠期糖尿病后糖尿病预防项目的实施组成部分：范围综述。

IF 6.4 2区医学

Current Diabetes Reports Pub Date : 2025-11-24 DOI: 10.1007/s11892-025-01615-0

Katelyn Sushko, Megan Racey, Paige Alliston, Diana Sherifali, Kelly Smith, Lorraine Lipscombe

{"title":"Implementation Components of Diabetes Prevention Programs after Gestational Diabetes Mellitus: A Scoping Review.","authors":"Katelyn Sushko, Megan Racey, Paige Alliston, Diana Sherifali, Kelly Smith, Lorraine Lipscombe","doi":"10.1007/s11892-025-01615-0","DOIUrl":"10.1007/s11892-025-01615-0","url":null,"abstract":"Purpose of review: To synthesize the components of diabetes prevention programs (DPPs) after gestational diabetes mellitus (GDM) and how they relate to factors that influence implementation. We conducted a scoping review of the literature using MEDLINE, Embase, PsychINFO, and Emcare. We provided a narrative description of intervention components based on the Template for Intervention Description and Replication (TIDieR) and the study results based on the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework.Recent findings: Seventeen included studies described DPPs after GDM. Recruitment typically began during pregnancy, while interventions started postpartum, with higher reach and participation rates for studies that recruited during pregnancy. The included DPPs used face-to-face delivery, virtual delivery, or a combination. Many programs were individual, but a few had a group component. Program duration varied from one month to three years. The available data highlighted the need to increase engagement, particularly for minority groups, and utilize flexibility and tailoring of program components and delivery to optimize retention, impact and sustainability. Significant barriers to the successful implementation of DPPs after GDM exist; the reporting of intervention components and implementation outcomes in the existing studies is variable. Validated frameworks, including RE-AIM, should be integrated into intervention development, implementation and evaluation.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"58"},"PeriodicalIF":6.4,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145586110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychological Impact of Screening for Risk of Type 1 Diabetes: an Update. 1型糖尿病风险筛查的心理影响：最新进展。

IF 6.4 2区医学

Current Diabetes Reports Pub Date : 2025-11-13 DOI: 10.1007/s11892-025-01612-3

Suzanne Bennett Johnson, Holly O'Donnell, Laura B Smith, Jessica Melin

{"title":"Psychological Impact of Screening for Risk of Type 1 Diabetes: an Update.","authors":"Suzanne Bennett Johnson, Holly O'Donnell, Laura B Smith, Jessica Melin","doi":"10.1007/s11892-025-01612-3","DOIUrl":"10.1007/s11892-025-01612-3","url":null,"abstract":"Purpose of review: Summarize recent literature on: understanding of and emotional reactions to type 1 diabetes (T1D) risk; willingness to be screened; behavioral responses to T1D-risk screening results; and provider attitudes/concerns about general population screening.Recent findings: Difficulty understanding what it means to be at increased risk for T1D is common; anxiety about increased risk may occur, particularly in multiple islet autoantibody positive (IA+) individuals. Many are hesitant to be screened or to be medically monitored if at increased risk. Those at risk may engage in behaviors to try to prevent T1D. Providers are often cautious about general population screening, with concerns about associated anxiety paramount. Understanding the psychosocial implications of T1D-risk screening is critical to its success. Interventions are needed to improve understanding of the purpose, procedures and consequences of screening, what it means to be at risk, and ways to cope with associated anxiety. The psychosocial impact of a Stage 1 or Stage 2 T1D diagnosis needs clarification and the availability of drugs to delay disease onset is likely to have a significant impact on the decision to be screened and monitored if at-risk for T1D. The impact of screening on children as well as their role in screening/medical monitoring decision-making needs to be addressed.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"57"},"PeriodicalIF":6.4,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145502497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Scoping Review on the Role of the Microbiome as a Factor in the Bidirectional Association Between Obesity and Depression. 微生物组在肥胖和抑郁之间双向关联中的作用综述。

IF 6.4 2区医学

Current Diabetes Reports Pub Date : 2025-10-29 DOI: 10.1007/s11892-025-01607-0

Gabrielle Beswick, Nicole Major, Cleo Hendrickson, Vivek Kumar, Madi Waller, Zuha Durrani, Sophie Hotchkiss, Asem Bala, Valerie H Taylor

{"title":"A Scoping Review on the Role of the Microbiome as a Factor in the Bidirectional Association Between Obesity and Depression.","authors":"Gabrielle Beswick, Nicole Major, Cleo Hendrickson, Vivek Kumar, Madi Waller, Zuha Durrani, Sophie Hotchkiss, Asem Bala, Valerie H Taylor","doi":"10.1007/s11892-025-01607-0","DOIUrl":"10.1007/s11892-025-01607-0","url":null,"abstract":"Purpose of review: Obesity is a chronic illness highly comorbid with mental health conditions, particularly depression. Among the factors involved in this association, inflammation is a consistently identified link. This review explores the emerging role of the gut microbiota as a modulator of inflammation and its potential involvement in the pathophysiological processes linking obesity and depression.Recent findings: Chronic low-grade inflammation is observed in both obesity and depressive disorders. Alterations in gut microbiota are increasingly implicated in inflammatory mechanisms, including increased intestinal permeability, immune activation, and short-chain fatty acid (SCFA) production, influencing leukocyte function and cytokine production. Additionally, both obesity and depression are associated with altered microbial composition. The gut microbiome contributes to chronic inflammation relevant to the pathophysiology of both obesity and depression. Accumulating evidence highlights the need for further research into how gut microbiota influences inflammatory mechanisms observed in both obesity and depression.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":"25 1","pages":"56"},"PeriodicalIF":6.4,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0